Top Banner
National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/ poster: TUPDC0103
4

National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011

Jan 19, 2016

Download

Documents

macon

National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011. R. Suzanne Beard, Ph.D. Abstract/poster : TUPDC0103. Background. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011

National Prevalence of Transmitted HIV Drug Resistance

in Swaziland in 2011

R. Suzanne Beard, Ph.D.

Abstract/poster: TUPDC0103

Page 2: National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011

Background Assessed the national level of transmitted drug

resistance (TDR) in recently HIV-infected adults (18-49 yrs.) using samples collected from seroconverters and acutely HIV-infected persons enrolled between 2010-2011 in the Swaziland HIV Incidence Measurement Survey (SHIMS)

18,172 adults completed household-based counseling and rapid HIV testing 13 seronegative, NAT positive (acute) 11,232 HIV-negative individuals had repeat HIV testing

six months later, 145 seroconverted (SC)

151 out of 158 HIV-positive samples were available for HIVDR analysis

Abstract/poster: TUPDC0103

Page 3: National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011

Genotyping was performed with 3 assays: sequencing based (in-house), multiplex allele-specific (MAS), and allele-specific real-time PCR (AS-PCR)

detection limits of minor mutations of 20%, 1.6-12.5% and 0.2-1.7% respectively

TDR mutations were determined by Calibrated Population Resistance tool using the 2009 WHO DR mutation listAbstract/poster: TUPDC0103

Resistance Profile by Assay for Patients With TDR

Specimen # category

In-house Result

MAS Result

AS-PCR Result

20* SC K103N21 SC V106A V106AV31 SC Y181C33 SC Y181C

48 SC M46I+

72 SC V106M85 SC Y181C101 SC V106M103 SC V106M, Y181C122 SC Y181C Y181C Y181C141 acute Y181C148 acute K103N K103N K103N, Y181C151 acute Y181C148 acute K65R

4 3 13NNRTI

2.13%NNRTI

2.13% 7.91%* positive by in-house but was not successfully sequenced

designed to detect any PI mutations

Total Number of Major DR Mutations

+ the MAS-DR is not designed to detect this PI mutation and AS-PCR is not

Prevelence of TDR

Page 4: National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011

Center for Global Health

Division of Global HIV/AIDS

Conclusions These findings provide the first estimate of the

national prevalence of TDR, using samples from a nationally representative cohort of HIV seroconverters and acutely HIV-infected individuals

Using WHO definitions, the TDR level in Swaziland is: low (<5%) based on the sequencing-based in-

house or more sensitive MAS assay moderate (5-15%) based on the ultrasensitive

AS-PCR Further work needs to be done to determine the

clinical significance of low-frequency DR mutations

Surveillance of TDR in recently HIV-1-infected populations can inform treatment programs on the efficacy of current ART regimens available

Abstract/poster: TUPDC0103